Harvey Dubiner

2.5k total citations
33 papers, 1.3k citations indexed

About

Harvey Dubiner is a scholar working on Ophthalmology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine. According to data from OpenAlex, Harvey Dubiner has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Ophthalmology, 14 papers in Public Health, Environmental and Occupational Health and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Harvey Dubiner's work include Glaucoma and retinal disorders (32 papers), Ocular Surface and Contact Lens (14 papers) and Retinal Diseases and Treatments (13 papers). Harvey Dubiner is often cited by papers focused on Glaucoma and retinal disorders (32 papers), Ocular Surface and Contact Lens (14 papers) and Retinal Diseases and Treatments (13 papers). Harvey Dubiner collaborates with scholars based in United States, Switzerland and Spain. Harvey Dubiner's co-authors include Amanda M. VanDenburgh, William C. Stewart, Monte S. Dirks, Kenneth Sall, Kim M. Strohmaier, Ingrid Adamsons, Ellen Snyder, Brian Levy, Casey Kopczynski and Gary D. Novack and has published in prestigious journals such as Ophthalmology, American Journal of Ophthalmology and Investigative Ophthalmology & Visual Science.

In The Last Decade

Harvey Dubiner

33 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harvey Dubiner United States	19	1.1k	723	445	158	151	33	1.3k
Monte S. Dirks United States	12	796 0.7×	464 0.6×	329 0.7×	46 0.3×	107 0.7×	20	975
Lucia Tanga Italy	15	606 0.6×	102 0.1×	236 0.5×	147 0.9×	43 0.3×	42	744
Eiichi Shirasawa Japan	16	439 0.4×	147 0.2×	217 0.5×	261 1.7×	20 0.1×	40	728
Nava Naveh Israel	13	342 0.3×	69 0.1×	209 0.5×	73 0.5×	34 0.2×	40	550
S M Podos United States	11	504 0.5×	118 0.2×	121 0.3×	205 1.3×	69 0.5×	19	613
Yukihiro Miwa Japan	18	366 0.3×	58 0.1×	265 0.6×	252 1.6×	14 0.1×	39	726
S. Lerner Argentina	11	774 0.7×	79 0.1×	229 0.5×	388 2.5×	85 0.6×	21	946
Yalong Dang China	17	442 0.4×	39 0.1×	245 0.6×	170 1.1×	87 0.6×	46	614
Reiko Yamagishi Japan	15	284 0.3×	56 0.1×	75 0.2×	223 1.4×	33 0.2×	30	499
Azucena H Kakazu United States	13	91 0.1×	236 0.3×	245 0.6×	156 1.0×	4 0.0×	21	557

Countries citing papers authored by Harvey Dubiner

Since Specialization

Citations

This map shows the geographic impact of Harvey Dubiner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harvey Dubiner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harvey Dubiner more than expected).

Fields of papers citing papers by Harvey Dubiner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harvey Dubiner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harvey Dubiner. The network helps show where Harvey Dubiner may publish in the future.

Co-authorship network of co-authors of Harvey Dubiner

This figure shows the co-authorship network connecting the top 25 collaborators of Harvey Dubiner. A scholar is included among the top collaborators of Harvey Dubiner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harvey Dubiner. Harvey Dubiner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dubiner, Harvey, et al.. (2017). Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clinical ophthalmology. Volume 11. 669–681. 10 indexed citations

Brandt, James D., Harvey Dubiner, Kenneth Sall, et al.. (2017). Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring. Ophthalmology. 124(10). 1565–1566. 49 indexed citations

Myers, Jonathan S., et al.. (2016). A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 32(8). 555–562. 42 indexed citations

González, Victoria, Javier Moreno‐Montañés, Kenneth Sall, et al.. (2016). Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Investigative Ophthalmology & Visual Science. 57(12). 3023–3023. 11 indexed citations

Fechtner, Robert D., et al.. (2016). Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye. 30(10). 1343–1350. 15 indexed citations

Bacharach, Jason, Harvey Dubiner, Brian Levy, Casey Kopczynski, & Gary D. Novack. (2014). Double-masked, Randomized, Dose–Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure. Ophthalmology. 122(2). 302–307. 117 indexed citations

Dubiner, Harvey & Douglas A. Hubatsch. (2014). Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. BMC Ophthalmology. 14(1). 151–151. 7 indexed citations

Realini, Tony, Quang H. Nguyen, Grégory Katz, & Harvey Dubiner. (2013). Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye. 27(7). 841–847. 24 indexed citations

Myers, Jonathan S., et al.. (2013). A Randomized, Phase II Study of Trabodenoson (INO-8875) in Adults with Ocular Hypertension (OHT) or Primary Open-Angle Glaucoma (POAG). Investigative Ophthalmology & Visual Science. 54(15). 2621–2621. 7 indexed citations

10.

Lane, Stephen S., Harvey Dubiner, Randy J. Epstein, et al.. (2012). A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction. Cornea. 31(4). 396–404. 212 indexed citations

11.

Dubiner, Harvey & Robert J. Noecker. (2012). Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clinical ophthalmology. 6. 525–525. 8 indexed citations

12.

Faulkner, Robert, Najam A. Sharif, Kenneth Sall, et al.. (2010). Aqueous Humor Concentrations of Bimatoprost Free Acid, Bimatoprost and Travoprost Free Acid in Cataract Surgical Patients Administered Multiple Topical Ocular Doses of LUMIGAN ^® or TRAVATAN ^®. Journal of Ocular Pharmacology and Therapeutics. 26(2). 147–156. 29 indexed citations

13.

Dubiner, Harvey, Theresa Landry, Michael V.W. Bergamini, et al.. (2004). Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clinical Therapeutics. 26(1). 84–91. 74 indexed citations

14.

Greiner, Jack V., Thomas K. Mundorf, Harvey Dubiner, et al.. (2003). Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. American Journal of Ophthalmology. 136(6). 1097–1105. 26 indexed citations

15.

Dubiner, Harvey, et al.. (2001). A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial. Clinical Therapeutics. 23(12). 1969–1983. 38 indexed citations

16.

Stewart, William C., Douglas G. Day, Elizabeth D. Sharpe, et al.. (1999). Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. American Journal of Ophthalmology. 128(6). 692–696. 35 indexed citations

17.

Strohmaier, Kim M., Ellen Snyder, Ingrid Adamsons, & Harvey Dubiner. (1999). Dorzolamide-timolol combination versus concomitant administration of its components: authors’ reply. Ophthalmology. 106(6). 1045–1045. 6 indexed citations

18.

Strohmaier, Kim M., Ellen Snyder, Harvey Dubiner, & Ingrid Adamsons. (1998). The efficacy and safety of the Dorzolamide—timolol combination versus the concomitant administration of its components11Ms. Strohmaier and Drs. Snyder and Adamsons are employees of Merck & Co., Inc, the manufacturer of the dorzolamide-timolol combination. Dr. DuBiner has no proprietary interest in the dorzolamide-timolol combination or Merck.. Ophthalmology. 105(10). 1936–1944. 108 indexed citations

19.

Dubiner, Harvey, Richard S. Hill, Herbert Kaufman, et al.. (1996). Timolol Hemihydrate vs Timolol Maleate to Treat Ocular Hypertension and Open-Angle Glaucoma. American Journal of Ophthalmology. 121(5). 522–528. 12 indexed citations

20.

Dubiner, Harvey, et al.. (1989). Effect of Intracameral Carbachol on Intraocular Pressure After Cataract Extraction. American Journal of Ophthalmology. 107(2). 133–136. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact